Caxton Associates (New York)’s Adverum Biotechnologies ADVM Stock Holding History

Caxton Associates (New York)’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-32,554	Closed	-$426K	–	547
2022 Q1	$426K	Hold	32,554	–	–	0.03%	286
2021 Q4	$573K	Buy	32,554 +20,069	+161%	+$402K	0.06%	245
2021 Q3	$271K	Buy	12,485 +9,663	+342%	+$247K	0.03%	340
2021 Q2	$99K	Buy	+2,822	New	+$152K	0.01%	451
2020 Q2	–	Sell	-2,657	Closed	-$260K	–	447
2020 Q1	$260K	Buy	+2,657	New	+$310K	0.05%	290

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Caxton Associates (New York)'s ADVM Position: Q2 2022 in Review

Caxton Associates (New York) sold out of Adverum Biotechnologies (ADVM) in Q2 2022, closing a stake of 32,554 shares — an estimated $426K sold.

Caxton Associates (New York) first reported a position in ADVM in Q1 2020 and held it in 5 quarters. The position peaked at $573K in Q4 2021. 77 funds tracked by Wall St. Rank hold ADVM as of Q2 2022.

Caxton Associates (New York) reported no remaining Adverum Biotechnologies position as of Q2 2022 after selling out during the quarter.
Caxton Associates (New York) sold 32,554 Adverum Biotechnologies shares in Q2 2022, an estimated $426K.
Caxton Associates (New York) first reported a position in Adverum Biotechnologies in Q1 2020 and held it in 5 quarters.
Caxton Associates (New York)'s Adverum Biotechnologies position peaked at $573K in Q4 2021.
77 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2022.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.